S Negrier, B Escudier, C Lasset, JY Douillard … - The New England journal of medicine, 1998 - nejm.highwire.org Results Response rates were 6.5 percent, 7.5 percent, and 18.6 percent (P<0.01)
for the groups receiving interleukin-2, interferon alfa-2a, and interleukin-2
plus interferon alfa-2a, respectively. At one year, the event-free survival ... Cited by 580 - Related articles - BL Direct - All 6 versions
RC Flanigan, SE Salmon, BA Blumenstein, SI … - The New England journal of medicine, 2001 - nejm.highwire.org Methods We randomly assigned patients with metastatic renal-cell cancer who were
acceptable candidates for nephrectomy to undergo radical nephrectomy followed by
therapy with interferon alfa-2b or to receive interferon alfa-2b therapy ... Cited by 560 - Related articles - BL Direct - All 7 versions
RM Bukowsky - CA A Cancer Journal for Clinicians - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 229 - Related articles - BL Direct - All 3 versions
- ►jcojournal.org JD Hainsworth, JA Sosman, DR Spigel, DL … - Journal of Clinical Oncology, 2005 - jcojournal.org PURPOSE: To evaluate the efficacy and toxicity of combined treatment with two
targeted agents, an antibody against vascular endothelial growth factor
(bevacizumab) and an epidermal growth factor receptor tyrosine kinase ... Cited by 230 - Related articles - All 11 versions
NJ Vogelzang, WM Stadler - The Lancet, 1998 - Elsevier In the USA, the incidence of kidney cancer has increased 43% since 1973. The
risk of the disorder is higher in men than in women and increases with age. The
von Hippel-Lindau tumour-suppressor gene is inactivated in over 75% of ... Cited by 188 - Related articles - BL Direct - All 6 versions
- ►ascopubs.org [PDF] JP Dutcher, S Creekmore, GR Weiss, K … - Journal of Clinical Oncology, 1989 - jco.ascopubs.org The mononuclear cell population was then expanded in vitro and demonstrated
cytotoxic activity. The activated autologous cells were subsequently reinfused
into the patients with additional IL-2.7 Responses were noted at the higher ... Cited by 173 - Related articles - All 5 versions
KA Foon… - Cancer Res, 1989 - AACR Immunotherapy is divided into two overlapping categories, active and passive.
The goal of active immunotherapy is the stimulation of host ant
¡tumorimmunity, either cellular or hu moral. This can be accomplished in ... Cited by 166 - Related articles - All 3 versions
TM Law, RJ Motzer, M Mazumdar, KW Sell, P … - CA A Cancer Journal for Clinicians - interscience.wiley.com Methods. A randomized Phase III trial was conducted in patients with RCC
comparing continuous intravenous infusion (CI) IL-2 alone with CI IL-2 plus LAK.
Interleukin-2 was administered at 3 × 10 6 U/m 2 /day on days 1-5, 13-17, ... Cited by 162 - Related articles - BL Direct - All 3 versions
- ►ascopubs.org [PDF] DT Sleijfer, RA Janssen, J Buter, EG De … - Journal of Clinical Oncology, 1992 - jco.ascopubs.org Purpose: A single-institution phase II study was under- taken to evaluate the
efficacy and toxicity of interleukin-2 (IL-2) administered by subcutaneous
injection. Patients and Methods: Twenty-seven unselected pa- tients (15 ... Cited by 148 - Related articles - All 15 versions
